$ T" l: N4 n' I临床上有依维莫司联合EGFR TKI作为易/特耐药之后的方案的研究: 3 a( t! x7 n, }1 wEverolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer.7 V5 k7 G1 P J1 z, `7 p http://www.ncbi.nlm.nih.gov/pubmed/229681847 C$ B$ D: N4 F+ M* R